Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
Issue Date
2022-08-17Keywords
PARP inhibitorsendocrine therapy
immune checkpoint inhibitors
neoadjuvant
pathological complete response
platinum agents
Metadata
Show full item recordJournal
Cancer management and researchDOI
10.2147/CMAR.S341466PubMed ID
35999966Item Type
ArticleLanguage
enISSN
1179-1322ae974a485f413a2113503eed53cd6c53
10.2147/CMAR.S341466
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting.
- Authors: Desai NV, Tan AR
- Issue date: 2023 May
- Overview of resistance to systemic therapy in patients with breast cancer.
- Authors: Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN
- Issue date: 2007
- Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
- Authors: Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G
- Issue date: 2020
- Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
- Authors: Harbeck N, Gluz O
- Issue date: 2017 Aug